Fig. 6.

CD151 downregulation influenced the VCAM-1 expression through the p38/NF-κB pathway. a In vitro experiment design with inhibitor treatment. SB203580 (p38 inhibitor, 30 μM), SP600125 (JNK inhibitor, 30 μM), PD98059 (ERK 1/2 inhibitor, 30 μM), and PDTC (NF-κB inhibitor, 50 μM) were applied in the LV Vehicle + OGD group. b VCAM-1, c ICAM-1, d E-selectin, and e CD9 expression levels after inhibitor application (n = 3 per group). *, ***, and **** vs. LV Vehicle + OGD indicate p < 0.05, 0.001, and 0.0001, respectively. IκB α degeneration (f) and p65 translocation from the g cytoplasm to the h nucleus were used to evaluate the NF-κB activation (n = 3 per group). * and ** vs. LV Vehicle + OGD indicate p < 0.05 and 0.01, respectively